December 20, 2017
TRANS GENIC INC.
(Code No.2342 TSE Mothers)

TRANS GENIC to Enter into Non-Exclusive Licensing Agreement on Highly Efficient CRISPR/Cas9 Knock-in Method

TRANS GENIC INC. (CEO: Kenji Fukunaga, Fukuoka-city, Fukuoka, Japan) hereby announces that, it has entered into non-exclusive domestic licensing agreement with Tokyo Medical and Dental University (President: Yasuyuki Yoshizawa, Bunkyo-ku, Tokyo, Japan) on highly efficient CRISPR/Cas9 knock-in method.

The genome editing technology with the use of this method enables point mutagenesis and large-sized recombination in zygotes efficiently. It is considered to extend the range in application of genetically engineered mouse production service using CRISPR/Cas9 system.

TRANS GENIC works aggressively to adopt leading-edge technologies in addition to its advanced technologies accumulated in the business deployment as a pioneer of genetically engineered mouse production. This licensing is part of this effort, and expected to add more value to its existing services. TRANS GENIC will make a persistent effort to increase its sales by organizing cooperative system between non-clinical test service and genomics business.

This licensing will not have a material impact on the business result or financial performance for the fiscal term ending March 2018. TRANS GENIC will actively promote genetically engineered mouse production service for the enhancement of organizational performance and company value.

◆ Related products/service of TRANS GENIC:

Genetically engineered mice production service using genome editing technology (CRISPR/Cas9)

◆ Reference

Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice
Tomomi Aida, Keiho Chiyo, Takako Usami, Harumi Ishikubo, Risa Imahashi, Yusaku Wada, Kenji F Tanaka, Tetsushi Sakuma, Takashi Yamamoto and Kohichi Tanaka
Genome Biology (2015) 16:87

◆ Patent

JP 6190995 B, WO2016/080097

◆ Glossary: Highly Efficient CRISPR/Cas9 Knock-in Method

CRISPR/Cas9 system is an adaptive immune mechanism in bacteria. In recent years, it is widely applied as an efficient targeted genome editing technology.

The research group of Dr. Koichi Tanaka (Professor) and Dr. Tomomi Aida (Associate professor), Laboratory of Molecular Neuroscience, Medical Research Institute, Tokyo Medical and Dental University, indicated highly efficient method to induce mutagenesis, in particular, gene knock-in. In this method, Cas9 protein

combined with RNA is introduced directly without cloning into plasmid or RNA. This cloning-free CRISPR/Cas system enables highly specific gene knock-in for the on-target locus in large-sized genome, which was difficult in commonly used method

Contact for inquiries and additional information：
TRANS GENIC INC.
Yutaka Funabashi, Director
Telephone　+81-(0)3-6551-2601